Dutch Biotech Merus Raises €21.7 Million ($30.7 Million)
1/29/2010 6:42:50 AM
peHUB -- Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fund, Pfizer Inc. (New York), Bay City Capital (San Francisco), and LSP (Life Sciences Partners; Amsterdam). Merus’ seed investor Aglaia Oncology Fund (Bilthoven) also participated in this financing.
comments powered by